Cargando…

A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors

Combined agonist stimulation of the TNFR costimulatory receptors 4-1BB (CD137) and OX40(CD134) has been shown to generate supereffector CD8 T cells that clonally expand to greater levels, survive longer, and produce a greater quantity of cytokines compared to T cells stimulated with an agonist of ei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konstorum, Anna, Vella, Anthony T., Adler, Adam J., Laubenbacher, Reinhard C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659676/ https://www.ncbi.nlm.nih.gov/pubmed/31350431 http://dx.doi.org/10.1038/s41598-019-47333-y

Ejemplares similares

CD134/CD137 Dual Costimulation-Elicited IFN-γ Maximizes Effector T Cell Function but Limits Treg Expansion
por: Rose, Marie-Clare St., et al.
Publicado: (2013)

Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
por: Adler, Adam J., et al.
Publicado: (2013)

CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
por: Otano, Itziar, et al.
Publicado: (2021)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Breaking Immunological Tolerance through OX40 (CD134)
por: Bansal-Pakala, Pratima, et al.
Publicado: (2001)

The Role of OX40 (CD134) in T-Cell Memory Generation
por: Weinberg, Andrew D.
Publicado: (2010)

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
por: Labiano, Sara, et al.
Publicado: (2014)

4‐1BB costimulation promotes bystander activation of human CD8 T cells
por: Reithofer, Manuel, et al.
Publicado: (2020)

4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)

Evaluating the glycolytic potential of mouse costimulated effector CD8(+) T cells ex vivo
por: Agliano, Federica, et al.
Publicado: (2022)

Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012)

Multimeric forms of CD40 ligand (CD40L), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L), CD27L/CD70, and other TNFSFs as tools for adoptive cell therapy
por: Kornbluth, Richard S
Publicado: (2013)

OX40 (CD134) Controls Memory T Helper 2 Cells that Drive Lung Inflammation
por: Salek-Ardakani, Shahram, et al.
Publicado: (2003)

OX40 (CD134) Expression on T Regulatory Cells Is Related to Serious Hypertensive Disorders in Pregnancy
por: Kwiatek, Maciej, et al.
Publicado: (2023)

Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor
Publicado: (1994)

TCR-independent CD137 (4–1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation
por: Pichler, Andrea C., et al.
Publicado: (2023)

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells
por: Hombach, Andreas A., et al.
Publicado: (2012)

Clinical significance of costimulatory molecules CD40/CD40L and CD134/CD134L in coronary heart disease: A case-control study
por: Chen, Jun, et al.
Publicado: (2017)

Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells
por: Cohen, Sivan, et al.
Publicado: (2021)

CD137-CD137 Ligand Interactions in Inflammation
por: Kwon, Byungsuk
Publicado: (2009)

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
por: Zapata, Juan M., et al.
Publicado: (2018)

CD28 Costimulation Is Required for In Vivo Induction of Peripheral Tolerance in CD8 T Cells
por: Vacchio, Melanie S., et al.
Publicado: (2003)

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking
por: Turaj, Anna H., et al.
Publicado: (2018)

CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
por: Saoulli, Katina, et al.
Publicado: (1998)

Optimal CD8(+) T cell effector function requires costimulation-induced RNA-binding proteins that reprogram the transcript isoform landscape
por: Karginov, Timofey A., et al.
Publicado: (2022)

CD28, Costimulator or Agonist Receptor?
por: Margulies, David H.
Publicado: (2003)

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

4-1BB (CD137) and radiation therapy: A case report and literature review
por: Shiao, Jay C., et al.
Publicado: (2017)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
por: Liu, Guizhong, et al.
Publicado: (2023)

Two pathways of costimulation through CD28
por: Miller, Jim, et al.
Publicado: (2009)

A pathway of costimulation that prevents anergy in CD28- T cells: B7- independent costimulation of CD1-restricted T cells
Publicado: (1995)

Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
por: Fromm, George, et al.
Publicado: (2015)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

Receptor Avidity and Costimulation Specify the Intracellular Ca(2+) Signaling Pattern in Cd4(+)Cd8(+) Thymocytes
por: Freedman, Bruce D., et al.
Publicado: (1999)

Increased Soluble CD137 Levels and CD4+ T‐Cell‐Associated Expression of CD137 in Acute Atherothrombotic Stroke
por: He, Yang, et al.
Publicado: (2018)

OX40:OX40L axis: emerging targets for improving poxvirus‐based CD8(+) T‐cell vaccines against respiratory viruses
por: Goulding, John, et al.
Publicado: (2011)

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
por: Vinay, Dass S., et al.
Publicado: (2014)

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
por: Chen, Siqi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m191f0dkj7t0qb2q8vchoi51kb